Ranbaxy Receives Tentative Approval For Valsartan Tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valsartan Tablets, 40 mg, 80 mg, 160 mg and 320 mg. Total annual market sales for Valsartan Tablets were $1.3 billion (IMS - MAT: June 2007). [click link for full article]

More: continued here

Filed under: Cardiovascular on October 31st, 2007